KR100887264B1 - 로수바스타틴의 특성화를 위한 기준 표준물 - Google Patents

로수바스타틴의 특성화를 위한 기준 표준물

Info

Publication number
KR100887264B1
KR100887264B1 KR1020067013302A KR20067013302A KR100887264B1 KR 100887264 B1 KR100887264 B1 KR 100887264B1 KR 1020067013302 A KR1020067013302 A KR 1020067013302A KR 20067013302 A KR20067013302 A KR 20067013302A KR 100887264 B1 KR100887264 B1 KR 100887264B1
Authority
KR
South Korea
Prior art keywords
rosuvastatin
lactone
product
calcium
acetonitrile
Prior art date
Application number
KR1020067013302A
Other languages
English (en)
Korean (ko)
Other versions
KR20060098396A (ko
Inventor
니나 핀겔슈타인
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100887264(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20060098396A publication Critical patent/KR20060098396A/ko
Application granted granted Critical
Publication of KR100887264B1 publication Critical patent/KR100887264B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
KR1020067013302A 2003-12-02 2004-12-02 로수바스타틴의 특성화를 위한 기준 표준물 KR100887264B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52644903P 2003-12-02 2003-12-02
US60/526,449 2003-12-02
PCT/US2004/040329 WO2005056534A1 (en) 2003-12-02 2004-12-02 Reference standard for characterization of rosuvastatin

Publications (2)

Publication Number Publication Date
KR20060098396A KR20060098396A (ko) 2006-09-18
KR100887264B1 true KR100887264B1 (ko) 2009-03-06

Family

ID=34676616

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067013302A KR100887264B1 (ko) 2003-12-02 2004-12-02 로수바스타틴의 특성화를 위한 기준 표준물

Country Status (13)

Country Link
US (6) US7244844B2 (US07692009-20100406-C00002.png)
EP (1) EP1689723B1 (US07692009-20100406-C00002.png)
JP (1) JP4733047B2 (US07692009-20100406-C00002.png)
KR (1) KR100887264B1 (US07692009-20100406-C00002.png)
CN (1) CN1894221B (US07692009-20100406-C00002.png)
AT (1) ATE507209T1 (US07692009-20100406-C00002.png)
CA (1) CA2546894C (US07692009-20100406-C00002.png)
DE (1) DE602004032465D1 (US07692009-20100406-C00002.png)
ES (1) ES2364143T3 (US07692009-20100406-C00002.png)
IL (1) IL175511A (US07692009-20100406-C00002.png)
PT (1) PT1689723E (US07692009-20100406-C00002.png)
TW (1) TWI351958B (US07692009-20100406-C00002.png)
WO (1) WO2005056534A1 (US07692009-20100406-C00002.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
CA2591439C (en) 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
AU2006329006B2 (en) * 2005-12-20 2013-02-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
EP2121631A2 (en) * 2007-03-13 2009-11-25 Teva Pharmaceutical Industries Ltd. Triol form of rosuvastatin
EP2189456A1 (en) * 2008-11-14 2010-05-26 LEK Pharmaceuticals d.d. New compounds prepared from omeprazole
JP5739820B2 (ja) 2008-12-30 2015-06-24 アークル インコーポレイテッド 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミン化合物
CN103454352B (zh) * 2013-07-30 2015-07-15 广东先强药业有限公司 一种hplc法测定瑞舒伐他汀钙的含量及其有关物质的方法
CN103776939A (zh) * 2014-02-11 2014-05-07 润泽制药(苏州)有限公司 瑞舒伐他汀钙制剂有关物质的制备检测方法
CN108398501A (zh) * 2018-03-02 2018-08-14 海南通用三洋药业有限公司 一种检测瑞舒伐他汀钙有关物质的方法
CN109020902B (zh) * 2018-07-23 2020-06-02 唯智医药科技（北京）有限公司 一种瑞舒伐他汀钙杂质及其制备方法与用途
CN114280181A (zh) * 2021-12-23 2022-04-05 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37314A (en) * 1863-01-06 Improved composition for lemonade
US633198A (en) * 1899-02-08 1899-09-19 Wilhelm Magnus Hoekerstedt Automatic-lighting torch.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
ES2110499T3 (es) 1991-06-19 1998-02-16 Shionogi & Co Intermediario opticamente activo y su produccion.
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9626746D0 (en) 1996-12-23 1997-02-12 Knoll Ag Process
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
WO2003016317A1 (en) 2001-08-16 2003-02-27 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
BR0311195A (pt) 2002-05-21 2005-02-22 Ranbaxy Lab Ltd Processo de preparação de rosuvastatina
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004052867A1 (en) 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
AU2003269478A1 (en) 2003-08-27 2005-03-16 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
US20070191318A1 (en) * 2003-10-22 2007-08-16 Yatendra Kumar Process for the preparation of amorphous rosuvastatin calcium
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
WO2006079611A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
US20090124803A1 (en) 2005-03-22 2009-05-14 Pandurang Balwant Deshpande Process for preparation of rosuvastatin
WO2006106526A1 (en) 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
CA2611920C (en) 2005-06-24 2015-05-05 Lek Pharmaceuticals D.D. Process for preparing pure amorphous rosuvastatin calcium
EP1912952B1 (en) 2005-06-24 2014-10-15 LEK Pharmaceuticals d.d. Process for preparing amorphous rosuvastatin calcium free of impurities
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. of Chromatography B: Biomedical Sciences & Applications, Vol. 772, No. 2, pp. 219-228

Also Published As

Publication number Publication date
ES2364143T3 (es) 2011-08-25
DE602004032465D1 (de) 2011-06-09
US20070249831A1 (en) 2007-10-25
US7692009B2 (en) 2010-04-06
US20070255059A1 (en) 2007-11-01
JP2007512354A (ja) 2007-05-17
US20050187234A1 (en) 2005-08-25
CA2546894A1 (en) 2005-06-23
US20090188305A1 (en) 2009-07-30
EP1689723B1 (en) 2011-04-27
CA2546894C (en) 2009-09-08
TWI351958B (en) 2011-11-11
JP4733047B2 (ja) 2011-07-27
US7244844B2 (en) 2007-07-17
IL175511A0 (en) 2006-09-05
ATE507209T1 (de) 2011-05-15
PT1689723E (pt) 2011-07-06
US20070249830A1 (en) 2007-10-25
US7692010B2 (en) 2010-04-06
CN1894221B (zh) 2012-08-08
US20070244321A1 (en) 2007-10-18
US7692008B2 (en) 2010-04-06
IL175511A (en) 2011-11-30
US7741482B2 (en) 2010-06-22
EP1689723A1 (en) 2006-08-16
KR20060098396A (ko) 2006-09-18
WO2005056534A1 (en) 2005-06-23
CN1894221A (zh) 2007-01-10
TW200522959A (en) 2005-07-16
US8487097B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
US7692010B2 (en) Reference standard for characterization of rosuvastatin
JPH02250870A (ja) コレステロール生合成抑制性化合物
JP2007533764A (ja) ロスバスタチンアルキルエーテルを含まないロスバスタチンおよびその塩およびそれらを製造する方法
JPH0641448B2 (ja) ３−デメチルメバロン酸誘導体
JP2007512357A (ja) 不純物を実質的に含まないアトルバスタチンカルシウムの形態を調製するための方法
US7851624B2 (en) Triol form of rosuvastatin and synthesis of rosuvastatin
US7884226B2 (en) Purification of rosuvatatin intermediate by thin film evaporation and chemical method
JP5330225B2 (ja) トリオール型ロスバスタチン
US20110112165A1 (en) Atorvastatin-aliskiren
Schneider et al. Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection
CN101631777A (zh) 罗苏伐他汀的三醇形式

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130215

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20140213

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20150220

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20160218

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20170216

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20190214

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20200213

Year of fee payment: 12